Clinical Trial

REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harvesting the patient's own stem cells (expressing KRT5/P63 markers), expanding them ex vivo, and administering them via bronchoscopic infusion to regenerate damaged lung tissue.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-22; most recent amendment 2026-07-18.
Status change: Not Yet Recruiting → Recruiting 2026-07-17
Trial Details
NCT Number NCT06998706
Lead Sponsor Ruijin Hospital
Conditions Interstitial Lung Disease (ILD)
Enrollment 10 participants
Start Date 2025-06-19
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28